Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Americo Padilla

Child & Adolescent Psychiatry Miami, FL Medical Doctor

NPI 1174564231 CMS profile 937593

3200 Sw 60Th Ct, Miami, FL 33155

Open in the dashboard

General payments

$10,665

181 records reported · program years 2019–2025

Research payments

$41,139

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,634,153 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Americo Padilla of Miami, FL is reported in the CMS Open Payments database as having received $10,665 across 181 general payments and $41,139 in research payments paid to them. Separately, studies naming them as principal investigator received $1,634,153 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $298 17
2024 General $304 13
2023 General $569 27
2023 Research $40,725 5
2022 General $773 29
2021 General $404 18
2020 General $1,451 18
2019 General $6,867 59
2019 Research $414 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Americo Padilla
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Americo Padilla were reported at $298. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Americo Padilla Child & Adolescent Psychiatry median Middle half National median
2019 $6,867 $129 $42–$419 $163
2020 $1,451 $81 $28–$226 $114
2021 $404 $115 $31–$326 $132
2022 $773 $124 $40–$382 $149
2023 $569 $130 $45–$420 $160
2024 $304 $141 $42–$490 $164
2025 $298 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $6,873 51 payments
  2. Sunovion Pharmaceuticals Inc. $1,223 23 payments
  3. Corium, Inc. $717 35 payments
  4. Tris Pharma Inc $554 21 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $423 17 payments
  6. Supernus Pharmaceuticals, Inc. $293 14 payments
  7. Shire North American Group Inc $265 9 payments
  8. Otsuka America Pharmaceutical, Inc. $140 2 payments
  9. Vertical Pharmaceuticals, LLC $74 4 payments
  10. Janssen Pharmaceuticals, Inc $36 1 payment
  11. Other $68 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,160 5 payments
  2. Food and Beverage $4,573 173 payments
  3. Travel and Lodging $932 3 payments
Products named General payments · program years 2019–2025
  1. Jornay PM 20mg capsules (Bottle of 100) $6,173 25 payments
  2. LATUDA $1,223 23 payments
  3. Azstarys $717 35 payments
  4. Dyanavel XR $471 15 payments
  5. JORNAY PM Central Nervous Stimulant ADHD $428 13 payments
  6. TRINTELLIX $375 15 payments
  7. JORNAY PM Central Nervous System Stimulant $272 13 payments
  8. Qelbree $237 11 payments
  9. VYVANSE $195 10 payments
  10. REXULTI $140 2 payments
  11. Other $399 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $40,725 5 payments
  2. Eli Lilly and Company $414 1 payment

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record